48 related articles for article (PubMed ID: 21725854)
1. Secondary hematological malignancies associated with temozolomide in patients with glioma.
Momota H; Narita Y; Miyakita Y; Shibui S
Neuro Oncol; 2013 Oct; 15(10):1445-50. PubMed ID: 23519741
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m
Muggeri A; Vago M; Pérez S; Rubio M; González C; Magariños C; Rosenberg M; Costa F; Pérez-Lloret S
Drugs R D; 2017 Sep; 17(3):427-434. PubMed ID: 28756607
[TBL] [Abstract][Full Text] [Related]
3. Are we done with dose-intense temozolomide in recurrent glioblastoma?
van den Bent MJ; Taal W
Neuro Oncol; 2014 Sep; 16(9):1161-3. PubMed ID: 25063550
[No Abstract] [Full Text] [Related]
4. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Ruban A; Berkutzki T; Cooper I; Mohar B; Teichberg VI
Invest New Drugs; 2012 Dec; 30(6):2226-35. PubMed ID: 22392507
[TBL] [Abstract][Full Text] [Related]
5. [Systemic treatment of adult gliomas: a narrative review].
Mangel L
Magy Onkol; 2024 Mar; 68(1):67-75. PubMed ID: 38484377
[TBL] [Abstract][Full Text] [Related]
6. Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
Muldoon LL; Pagel MA; Netto JP; Neuwelt EA
J Neurooncol; 2016 Feb; 126(3):447-54. PubMed ID: 26694547
[TBL] [Abstract][Full Text] [Related]
7. Forkhead box protein O3a promotes glioma cell resistance to temozolomide by regulating matrix metallopeptidase and β-catenin.
Sun D; Yang S; Zhang X; Li S; Wang L; Chen J; Qiu C; Xu K
Oncol Lett; 2021 Apr; 21(4):328. PubMed ID: 33692860
[TBL] [Abstract][Full Text] [Related]
8. Success at last: a molecular factor that informs treatment.
Lassman AB
Curr Oncol Rep; 2013 Feb; 15(1):47-55. PubMed ID: 23247800
[TBL] [Abstract][Full Text] [Related]
9. Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.
Shi ZD; Qian XM; Liu CY; Han L; Zhang KL; Chen LY; Zhang JX; Pu PY; Yuan XB; Kang CS;
CNS Neurosci Ther; 2013 Feb; 19(2):98-108. PubMed ID: 23230963
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in malignant gliomas: current use and future targets.
Villano JL; Seery TE; Bressler LR
Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
[TBL] [Abstract][Full Text] [Related]
11. Optimal role of temozolomide in the treatment of malignant gliomas.
Stupp R; van den Bent MJ; Hegi ME
Curr Neurol Neurosci Rep; 2005 May; 5(3):198-206. PubMed ID: 15865885
[TBL] [Abstract][Full Text] [Related]
12. Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Motomura K; Natsume A; Wakabayashi T
J Neurooncol; 2012 Jan; 106(1):209-11. PubMed ID: 21725854
[No Abstract] [Full Text] [Related]
13. Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Rosenthal MA; Ashley DL; Cher L
Intern Med J; 2002 Jul; 32(7):346-8. PubMed ID: 12088355
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
[TBL] [Abstract][Full Text] [Related]
15. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Wen PY
J Clin Oncol; 2010 Apr; 28(12):1977-9. PubMed ID: 20308652
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
